Dragons 'round the fleece again: STI571 versus α1 acid glycoprotein

Journal of the National Cancer Institute

Volumn 92, Issue 20, 2000, Pages 1626-1627

  Sausville, Edward A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OROSOMUCOID;

ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; EDITORIAL; GENE TARGETING; GROWTH INHIBITION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; OROSOMUCOID; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 0034684129     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Publius Ovidius Naso. The Metamorphoses Book VII
2. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
3. Structural organization of the bcr gene and its role in the Ph' translocation Nature
4. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
5. Clinical efficacy and safety of abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
6. Activity of an ABL specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemia, including chronic myelogenous leukemia in blast crisis
7. + leukemic cells to the Abl inhibitor STI571
8. Drug binding to human alpha-1-acid glycoprotein in health and disease
9. Characterization and drug binding sites on alpha 1-acid glycoprotein
10. Evolution of human alpha 1-acid glycoprotein genes and surrounding Alu repeats
11. Negative correlation between alpha-1-acid-glycoprotein plasma levels and response to haloperidol in the acute treatment of schizophrenia
12. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha 1-acid glycoprotein
13. PKC412 - A protein kinase inhibitor with a broad therapeutic potential
14. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
15. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: A frequency-domain fluorescence spectroscopic study
16. Animal models for studying the action of topoisomerase I targeted drugs
17. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
18. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth